Newsbenzinga
Merck, Daiichi Sankyo Scrap FDA Application for Lung Cancer Drug
· Published
Article summary
Merck and Daiichi Sankyo voluntarily withdrew their FDA application for a lung cancer drug due to insufficient data, though trials continue.
An excerpt from the original article.
Comments —
Loading comments…